Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Alita A Miller"'
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77874 (2013)
Staphylococcus aureus is a successful human pathogen that has developed several approaches to evade the immune system, including resistance strategies to prevent oxidative killing by immune cells. One mechanism by which this evasion occurs is by prod
Externí odkaz:
https://doaj.org/article/572d78d3434a4dd195238bdfef613cb6
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases. Sulbactam is a first generation β-lactamase inhibitor with activity limited to
Externí odkaz:
https://doaj.org/article/76b457a1b421402ca8d25e41e53dc80e
Publikováno v:
Clinical Infectious Diseases. 76:S194-S201
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination in late-stage development for the treatment of Acinetobacter infections, including those caused by multidrug-resistant strains. Durlobactam is a member of the d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69eb37cbb977328b4932649dd481ba75
https://doi.org/10.1093/cid/ciad095
https://doi.org/10.1093/cid/ciad095
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat serious Acinetobacter baumannii -calcoaceticus complex (ABC) infections, including carbapenem-non-susceptible and multidrug-resistant (MDR) isolates. The curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::569188f90cbb50c274048aefb9baf3c3
https://doi.org/10.1128/aac.00781-22
https://doi.org/10.1128/aac.00781-22
Publikováno v:
ACS Infectious Diseases. 6:1332-1345
The Centers for Disease Control and the World Health Organization have issued a list of priority pathogens for which there are dwindling therapeutic options, including antibiotic-resistant Neisseri...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b899521bfb9fa374d8e09827df18734
https://doi.org/10.1021/acsinfecdis.0c00021
https://doi.org/10.1021/acsinfecdis.0c00021
Autor:
Samir H. Moussa, Tommasi Ruben A, John P. Mueller, Nicole M. Carter, Alita A. Miller, Adam B. Shapiro, Sarah M. McLeod
Publikováno v:
ACS Infectious Diseases. 6:1389-1397
Multi-drug-resistant Enterobacteriales expressing a wide array of β-lactamases are emerging as a global health threat in both hospitals and communities. Although several intravenous drugs have recently been approved to address this need, there are n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89ddb08cd0396e93793c9000c1e0670b
https://doi.org/10.1021/acsinfecdis.0c00020
https://doi.org/10.1021/acsinfecdis.0c00020
Autor:
Khalid M. Dousa, David C. Nguyen, Sebastian G. Kurz, Magdalena A. Taracila, Christopher R. Bethel, William Schinabeck, Barry N. Kreiswirth, Sheldon T. Brown, W. Henry Boom, Richard S. Hotchkiss, Kenneth E. Remy, Frank J. Jacono, Charles L. Daley, Steven M. Holland, Alita A. Miller, Robert A. Bonomo
Publikováno v:
mBio
Mycobacterium abscessus (Mab) infections are a growing menace to the health of many patients, especially those suffering from structural lung disease and cystic fibrosis. With multidrug resistance a common feature and a growing understanding of pepti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab83dce280c4022d33c2d884c1d8c485
https://doi.org/10.1128/mbio.03529-21
https://doi.org/10.1128/mbio.03529-21
Publikováno v:
Frontiers in Microbiology
Frontiers in Microbiology, Vol 12 (2021)
Frontiers in Microbiology, Vol 12 (2021)
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases. Sulbactam is a first generation β-lactamase inhibitor with activity limited to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f64eb6e3808a0281315611b461e350b
http://europepmc.org/articles/PMC8328114
http://europepmc.org/articles/PMC8328114
Autor:
John P. Mueller, Douglas Lane, Scott A. Becka, Alita A. Miller, John P. O'Donnell, Krisztina M. Papp-Wallace, Adam B. Shapiro, Rekha G. Panchal, Elise T. Zeiser, John J. LiPuma
Publikováno v:
Antimicrob Agents Chemother
The Gram-negative bacterial genus Burkholderia includes several hard-to-treat human pathogens: two biothreat species, Burkholderia mallei (causing glanders) and B. pseudomallei (causing melioidosis), and the B. cepacia complex (BCC) and B. gladioli,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d605c1f5382c57c5c2511e7de5825a32
https://doi.org/10.1128/aac.01930-20
https://doi.org/10.1128/aac.01930-20
Publikováno v:
ACS infectious diseases. 7(1)
Mutations in KPC-2 and KPC-3 β-lactamase can confer resistance to the β-lactam/β-lactamase inhibitor antibacterial intravenous drug combination ceftazidime-avibactam, introduced in 2015. Avibactam was the first of the diazabicyclooctane class of n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0fd7d5d36b813b3030bad39045aa687
https://pubmed.ncbi.nlm.nih.gov/33291867
https://pubmed.ncbi.nlm.nih.gov/33291867